Author(s):
Anuradha Singh, Manish K Singh, Babita Kumar
Email(s):
anuradhampharm@gmail.com , mmanishsingh@gmail.com , director.pharmacy@sanskar.org
DOI:
10.52711/0975-4385.2026.00008 
Address:
Anuradha Singh1, Manish K Singh2, Babita Kumar1
1Sanskar College of Pharmacy and Research, Ghaziabad, UP.
2BN University Rajasthan.
*Corresponding Author
Published In:
Volume - 18,
Issue - 1,
Year - 2026
ABSTRACT:
Delivering therapeutics for neurodegenerative disorders is a complex process as there is involvement of blood brain barrier which prevents the entry of unwanted substances in the brain. Various therapeutic regimens are available showing effectiveness in mental health management but they show adverse effects and hence the conjugation of nanotechnology-based approaches with medicinal plants or phytomedicine have gained interest as phytochemicals are naturally abundant, and show lesser adverse effects than pharmacological regimens, also provide promising targeted delivery to the brain. Researchers have used nanotechnology approaches to encapsulate the herbal or phytomedicine so that the stability and bioavailability can be increased. Nanotechnology-based phytomedicine approaches have shown efficacy in crossing the blood brain barrier easily and increasing the concentration of therapeutics in the brain. This chapter provides a detailed overview on the role of nano phytomedicine in the management of neurodegenerative diseases such as depression and anxiety along with various phytochemicals showing neuroprotective properties and various challenges faced with implementing those in mental health management.
Cite this article:
Anuradha Singh, Manish K Singh, Babita Kumar. Challenges and Prospects of Nano-Phytomedicine in Anxiety and Depression Management. Research Journal of Pharmacognosy and Phytochemistry. 2026; 18(1):49-5. doi: 10.52711/0975-4385.2026.00008
Cite(Electronic):
Anuradha Singh, Manish K Singh, Babita Kumar. Challenges and Prospects of Nano-Phytomedicine in Anxiety and Depression Management. Research Journal of Pharmacognosy and Phytochemistry. 2026; 18(1):49-5. doi: 10.52711/0975-4385.2026.00008 Available on: https://rjpponline.org/AbstractView.aspx?PID=2026-18-1-8
REFERENCES:
1. American Psychological Association. Clinical practice guideline for the treatment of depression across three age cohorts. Washington (DC): American Psychological Association; 2019.
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392:1789–858.
3. Zhao YF, Verkhratsky A, Tang Y, Illes P. Astrocytes and major depression: the purinergic avenue. Neuropharmacology, 2022; 220: 109252.
4. Kircanski K, Joormann J, Gotlib IH. Cognitive aspects of depression. Wiley Interdiscip Rev Cogn Sci. 2012;3(3):301–13.
5. Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1)\:S1.
6. Hu P, Lu Y, Pan B-X, Zhang W-H. New insights into the pivotal role of the amygdala in inflammation-related depression and anxiety disorder. Int J Mol Sci. 2022;23(18):11076.
7. Penninx BW, Pine DS, Holmes EA, Reif A. Anxiety disorders. Lancet. 2021; 397(10277): 914–27.
8. Nasir M, Trujillo D, Levine J, Dwyer JB, Rupp ZW, Bloch MH. Glutamate systems in DSM-5 anxiety disorders: their role and a review of glutamate and GABA psychopharmacology. Front Psychiatry. 2020; 11:548505.
9. Fathinezhad Z, Sewell RDE, Lorigooini Z, Rafieian-Kopaei M. Depression and treatment with effective herbs. Curr Pharm Des. 2019;25(7):738–45.
10. Yasenyavskaya LA, Tsibizova MA, Samotrueva MA. Neurotrophic hypothesis of development of depression. Fiziol Cheloveka. 2024;50(2):142–52. doi:10.31857/s013116462402012
11. Gong W. Research progress on neural circuit mechanisms of depression. BIO Web Conf. 2023; 60:02021. doi:10.1051/bioconf/20236002021
12. Liu YZ, Liu Y, Lin W, He ZH, Zhang DD, Guan Q, et al. The core neural mechanisms underlying depression disorder: a meta-analysis of fMRI studies. Sci Sin Vitae. 2015; 45(12): 1214–23. doi:10.1360/N052015-00164
13. Bulubas L, Mezger E, Keeser D, Padberg F, Brunoni AR. Novel neuromodulatory approaches for depression: neurobiological mechanisms. In: Neuromodulation in psychiatry. 2019. p. 347–60. doi:10.1016/B978-0-12-813333-0.00031-7
14. World Health Organization. Depressive disorder (depression) \[Internet]. Geneva: WHO; 2024 \[cited 2024]. Available from: [https://www.who.int/news-room/fact-sheets/detail/depression] (https://www.who.int/news-room/fact-sheets/detail/depression)
15. Ajmire PP, Mirchapure VG. Exploring the neuropharmacological terrain of depression and anxiety: mechanisms, therapies, and future avenues. Int J Innov Sci Res Technol. 2024; 1065–72. doi:10.38124/ijisrt/ijisrt24sep941
16. Panigrahy A. Therapeutic approaches for treatment and management of depressive disorder: a comprehensive review. Int J Pharm Qual Assur. 2024; 15(2): 1040–7. doi:10.25258/ijpqa.15.2.75
17. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–4.
18. Jagtiani A, Khurana H, Malhotra N. Comparison of efficacy of ketamine versus thiopentone-assisted modified electroconvulsive therapy in major depression. Indian J Psychiatry. 2019; 61(3): 258–64.
19. Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013; 246:199–229.
20. Cutler AJ, Mattingly GW, Maletic V. Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder. Transl Psychiatry. 2023; 13: 228.
21. Aghajanian G. Serotonin and hallucinogens. Neuropsychopharmacology. 1999; 21(2 Suppl): 16S–23S. doi:10.1016/S0893-133X(98)00135-3
22. Millière R, Carhart-Harris RL, Roseman L, Trautwein FM, Berkovich-Ohana A. Psychedelics, meditation, and self-consciousness. Front Psychol. 2018; 9: 1475. doi:10.3389/fpsyg.2018.01475
23. Saravanan D, Khatoon BS, Winner GJ Sr. Unraveling the interplay: exploring the links between gut microbiota, obesity, and psychological outcomes. Cureus. 2023; 15: e49271.
24. Fond G, Miot S. La nanopsychiatrie: le rôle potentiel des nanotechnologies dans l’avenir de la psychiatrie. Une revue systématique. Encephale. 2013; 39(4): 252–7. doi:10.1016/j.encep.2013.02.002
25. Liu Z, Chen B, Xiang S, Hu S. Self-immolative nanocapsules precisely regulate depressive neuronal microenvironment for synergistic antidepression therapy. J Nanobiotechnol. 2023; 21: 2008–9. doi:10.1186/s12951-023-02008-9
26. Yadav K, Rani A, Tyagi AK, Babu MR. The application of nanotechnology and nanomaterials in depression: an updated review. Precis Nanomed. 2023. doi:10.33218/001c.82215
27. Rehman S, Nabi B, Pottoo FH, Baboota S, Ali J. Nanoparticle based gene therapy approach: a pioneering rebellion in the management of psychiatric disorders. Curr Gene Ther. 2020; 20(3): 164–73. doi:10.2174/1566523220666200607185903
28. Wang R, Zhang Y, Guo Y, Zeng W, Li J, Wu J, et al. Plant-derived nanovesicles: promising therapeutics and drug delivery nanoplatforms for brain disorders. Fundam Res. 2023. doi: 10.1016/j.fmre.2023.09.007
29. Aspatwar A, Nath R, Bhowmik R, Jesudasan R. Herbal-based nanosystems: a novel drug-delivery treatment procedure against neurodegenerative disorders. ChemRxiv [Preprint]. 2024. doi:10.26434/chemrxiv-2024-hh95h-v2
30. Izadi R, Bahramikia S, Akbari V. Green synthesis of nanoparticles using medicinal plants as an eco-friendly and therapeutic potential approach for neurodegenerative diseases: a comprehensive review. Front Neurosci. 2024. doi:10.3389/fnins.2024.1453499
31. Shah N, Kumari M, Sadhu P, Talele C, Rajput HS, Sapra R. Nano-herbal innovations: precision in therapeutic delivery. J Adv Zool. 2024; 45(1). doi:10.17762/jaz. v45i1.2976
32. Sarris J. Disruptive innovation in psychiatry. Ann N Y Acad Sci. 2022; 1512(1): 5–9. doi:10.1111/nyas.14764
33. Kisku A, Nishad A, Agrawal S, Paliwal R, Datusalia AK, Gupta G, et al. Recent developments in intranasal drug delivery of nanomedicines for the treatment of neuropsychiatric disorders. Front Med. 2024; 1–24.
34. Kumar R, Chhikara BS, Gulia K, Chhillar M. Review of nanotheranostics for molecular mechanisms underlying psychiatric disorders and commensurate nanotherapeutics for neuropsychiatry: the mind knockout. Nanotheranostics. 2021; 5(3): 288–308. doi:10.7150/ntno.49619
35. Huang Y, Guo X, Wu Y, Chen X, Feng L, Xie N, et al. Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment. Signal Transduct Target Ther. 2024; 9:34.
36. Yuan S, Ma T, Zhang YN, et al. Novel drug delivery strategies for antidepressant active ingredients from natural medicinal plants: the state of the art. J Nanobiotechnol. 2023; 21: 391. doi:10.1186/s12951-023-02159-9
37. Nurzyńska-Wierda R. Plants with potential importance in supporting the treatment of depression: current trends and research. Pharmaceuticals. 2024; 17(11): 1489. Doi:10.3390/ph17111489
38. Pires PC, Paiva-Santos AC, Veiga F. Nano and microemulsions for the treatment of depressive and anxiety disorders: an efficient approach to improve solubility, brain bioavailability and therapeutic efficacy. Pharmaceutics. 2022; 14(12): 2825. doi:10.3390/pharmaceutics14122825
39. Patel V, Aggarwal K, Dhawan A, Singh B, Shah P, Sawhney A, et al. Protein supplementation: the double-edged sword. Proc (Bayl Univ Med Cent). 2023; 37:118–26.
40. Holsboer F, Ising M. Precision psychiatry approach to treat depression and anxiety targeting the stress hormone system—V1b-antagonists as a case in point. Pharmacopsychiatry. 2024; 57(6): 263–74. doi:10.1055/a-2372-3549
41. Kabra A, Garg R, Brimson JM, Živković J, Almawash S, Ayaz M, et al. Mechanistic insights into the role of plant polyphenols and their nano-formulations in the management of depression. Front Pharmacol. 2022; 13: 1046599. doi:10.3389/fphar.2022.1046599
42. Antunes JL, Amado J, Veiga F, Paiva-Santos AC, Pires PC. Nanosystems, drug molecule functionalization and intranasal delivery: an update on the most promising strategies for increasing the therapeutic efficacy of antidepressant and anxiolytic drugs. Pharmaceutics. 2023; 15(3): 998. doi:10.3390/pharmaceutics15030998
43. Alberto M, Paiva-Santos AC, Veiga F, Pires PC. Intranasal nanoparticles for the treatment of depression and anxiety disorders. Appl Sci Events. 2022; 13853. Doi:10.3390/asec2022-13853
44. Ankit, Harsh Kumar, Kartikey Tiwari, Disha Sharma, Ashutosh Kumar, Shambhu Bhardwaj, Tanu Bhadauriya, Anuradha Verma, Anshika Garg, Babita Kumar. The Legacy and Advancement of Phytotherapeutics. Asian Journal of Pharmaceutical Research. 2025; 15(3): 333-6
45. Mutingwende FP, Kondiah PPD, Ubanako P, Marimuthu T, Choonara YE. Advances in nano-enabled platforms for the treatment of depression. Polymers. 2021; 13(9): 1431. Doi:10.3390/polym13091431
46. Rasad S, Tyagi AK, Aggarwal BB. Curcumin delivery systems: an overview. Phytother Res. 2014; 28(4): 545–58. doi:10.1002/ptr.5021
47. Kulkarni SK, Dhir A. Withania somnifera: an Indian ginseng. Indian J Exp Biol. 2008; 46(7):493–503. Ashok, Aspatwar., Ranajit, Nath., Ratul, Bhowmik., Rajesh, Jesudasan. (2024). Herbal-based nanosystems: A novel drug-delivery treatment procedure against neurodegenerative disorders. doi: 10.26434/chemrxiv-2024-hh95h-v2
48. Atul, Kabra, Ruchika, Garg., James, M., Brimson., Jelena, Živković., Saud, Almawash., Muhammad, Ayaz., Asif, Nawaz., Syed, Shams, ul, Hassan., Simona, Bungau. (2022). Mechanistic insights into the role of plant polyphenols and their nano-formulations in the management of depression. Frontiers in Pharmacology, 13 doi: 10.3389/fphar.2022.1046599
49. Margarida, Alberto, Ana, Cláudia, Paiva-Santos., Francisco, Veiga., Patrícia, C., Pires. (2022). Intranasal Nanoparticles for the Treatment of Depression and Anxiety Disorders. doi: 10.3390/asec2022-13853
50. Fadzai, P, Mutingwende, Pierre, P., D., Kondiah, Philemon, Ubanako., Thashree, Marimuthu., Yahya, E., Choonara. (2021). Advances in Nano-Enabled Platforms for the Treatment of Depression. Polymers, 13(9): 1431-. doi: 10.3390/POLYM13091431